Rating History for Genmab A/S (GMAB) by Leerink
| Date | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|
| 10/5/2026 | Asthika Goonewardene | New Coverage | Outperform (N/A) |
50.00 (N/A) |
34.75 (37.00) |
6.47% | Details |
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
| Date | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|
| 10/5/2026 | Asthika Goonewardene | New Coverage | Outperform (N/A) |
50.00 (N/A) |
34.75 (37.00) |
6.47% | Details |
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||